Drugs / ANX105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05288881 | Feb 2022 → Jun 2023 | — | Annexon, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANX105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05288881 ↗ |
| Route | Intravenous | “Participants will receive single-ascending doses of ANX105 administered by IV infusion.” NCT05288881 ↗ |